Germany · Delayed Price · Currency is EUR Molecure Statistics
Total Valuation
Molecure has a market cap or net worth of EUR 34.88 million. The enterprise value is 30.89 million.
| Market Cap | 34.88M |
| Enterprise Value | 30.89M |
Important Dates
The next estimated earnings date is Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 20.60M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +36.78% |
| Shares Change (QoQ) | -19.11% |
| Owned by Insiders (%) | 0.90% |
| Owned by Institutions (%) | 11.15% |
| Float | 19.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.41 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 6.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.40 |
| EV / Sales | 22.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.56 |
Financial Position
The company has a current ratio of 5.93, with a Debt / Equity ratio of 0.06.
| Current Ratio | 5.93 |
| Quick Ratio | 5.76 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | -502.09 |
Financial Efficiency
Return on equity (ROE) is -28.81% and return on invested capital (ROIC) is -17.55%.
| Return on Equity (ROE) | -28.81% |
| Return on Assets (ROA) | -17.15% |
| Return on Invested Capital (ROIC) | -17.55% |
| Return on Capital Employed (ROCE) | -27.25% |
| Revenue Per Employee | 19,332 |
| Profits Per Employee | -80,602 |
| Employee Count | 102 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.12% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -40.12% |
| 50-Day Moving Average | 1.60 |
| 200-Day Moving Average | 1.71 |
| Relative Strength Index (RSI) | 50.77 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Molecure had revenue of EUR 1.37 million and -5.72 million in losses. Loss per share was -0.25.
| Revenue | 1.37M |
| Gross Profit | 791,343 |
| Operating Income | -5.95M |
| Pretax Income | -5.72M |
| Net Income | -5.72M |
| EBITDA | -5.69M |
| EBIT | -5.95M |
| Loss Per Share | -0.25 |
Balance Sheet
The company has 5.26 million in cash and 1.31 million in debt, giving a net cash position of 3.96 million.
| Cash & Cash Equivalents | 5.26M |
| Total Debt | 1.31M |
| Net Cash | 3.96M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 20.96M |
| Book Value Per Share | 1.02 |
| Working Capital | 4.68M |
Cash Flow
In the last 12 months, operating cash flow was -12.04 million and capital expenditures -9,358, giving a free cash flow of -12.05 million.
| Operating Cash Flow | -12.04M |
| Capital Expenditures | -9,358 |
| Free Cash Flow | -12.05M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 57.65% |
| Operating Margin | -433.14% |
| Pretax Margin | -416.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Molecure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.78% |
| Shareholder Yield | -36.78% |
| Earnings Yield | -16.41% |
| FCF Yield | -34.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Molecure has an Altman Z-Score of 10.21 and a Piotroski F-Score of 2.
| Altman Z-Score | 10.21 |
| Piotroski F-Score | 2 |